After hours:
Chart Events
Performance Outlook
| Previous Close | 46.55 |
| Open | 46.77 |
| Bid | 45.22 x 900 |
| Ask | 45.38 x 800 |
| Day's Range | 45.22 - 46.77 |
| 52 Week Range | 31.45 - 81.72 |
| Volume | |
| Avg. Volume | 2,509,463 |
| Market Cap | 8.174B |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.32 |
| Earnings Date | Oct 30, 2023 - Nov 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.29 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CTLT
Related Research
- Catalent, Inc.Weekly Stock ListArgus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.RatingFair ValueEconomic Moat4 days agoArgus Research
GuruFocus.comIs Catalent Inc (CTLT) Set to Underperform? Analyzing the Factors Limiting Growth
Unraveling the Financial Metrics and Future Prospects of Catalent Inc
- Reuters
UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility
Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand. The U.S. company had said last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production. Such a move will help Moderna adjust to the sharp fall in demand for COVID vaccines as payers cut back orders for the shots, partly following the end of the public health emergency for the disease.
GuruFocus.comIs Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
Unpacking the Risks and Rewards of Investing in Catalent (CTLT)
